ClinicalTrials.gov record
Recruiting Phase 3 Interventional

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

ClinicalTrials.gov ID: NCT06963034

Public ClinicalTrials.gov record NCT06963034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Study identification

NCT ID
NCT06963034
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
284 participants

Conditions and interventions

Conditions

Interventions

  • NBI-1117568 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 7, 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027
Last update posted
Mar 5, 2026

2025 – 2027

United States locations

U.S. sites
21
U.S. states
10
U.S. cities
21
Facility City State ZIP Site status
Neurocrine Clinical Site Bryant Arkansas 72022 Recruiting
Neurocrine Clinical Site Little Rock Arkansas 72211 Recruiting
Neurocrine Clinical Site Anaheim California 92805 Recruiting
Neurocrine Clinical Site Pico Rivera California 90660 Recruiting
Neurocrine Clinical Site San Diego California 92123 Recruiting
Neurocrine Clinical Site Sherman Oaks California 91403 Recruiting
Neurocrine Clinical Site Torrance California 90504 Recruiting
Neurocrine Clinical Site Hollywood Florida 33024 Recruiting
Neurocrine Clinical Site Miami Lakes Florida 33016 Recruiting
Neurocrine Clinical Site Atlanta Georgia 30331 Recruiting
Neurocrine Clinical Site Decatur Georgia 30030 Recruiting
Neurocrine Clinical Site Snellville Georgia 30078 Recruiting
Neurocrine Clinical Site Chicago Illinois 60640 Recruiting
Neurocrine Clinical Site Gaithersburg Maryland 20877 Recruiting
Neurocrine Clinical Site Watertown Massachusetts 02472 Recruiting
Neurocrine Clinical Site Marlton New Jersey 08053 Recruiting
Neurocrine Clinical Site Staten Island New York 10314 Recruiting
Neurocrine Clinical Site The Bronx New York 10461 Recruiting
Neurocrine Clinical Site Austin Texas 78754 Recruiting
Neurocrine Clinical Site DeSoto Texas 75115 Recruiting
Neurocrine Clinical Site Houston Texas 77043 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06963034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06963034 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →